A
Anne Freimoser-Grundschober
Researcher at Hoffmann-La Roche
Publications - 68
Citations - 1755
Anne Freimoser-Grundschober is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: T cell & Antibody. The author has an hindex of 17, co-authored 62 publications receiving 1318 citations.
Papers
More filters
Patent
Bispecific t cell activating antigen binding molecules
Oliver Ast,Peter Bruenker,Tanja Fauti,Anne Freimoser-Grundschober,Christiane Jaeger,Christian Klein,Ekkehard Moessner,Pablo Umana +7 more
TL;DR: The present disclosure generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells as mentioned in this paper, and the present disclosure relates to polynucleotides encoding such bispeccific antigen bounding molecules, and vectors and host cells comprising such polynuclotides.
Journal ArticleDOI
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Christian Klein,Inja Waldhauer,Nicolini Valeria G,Anne Freimoser-Grundschober,Tapan K. Nayak,Danielle J. Vugts,Claire Dunn,Marije Bolijn,Jörg Benz,Martine Stihle,Sabine Lang,Michaele Roemmele,Hofer Thomas U,Erwin van Puijenbroek,David Wittig,Samuel Moser,Oliver Ast,Peter Brünker,Ingo H. Gorr,Sebastian Neumann,Maria Cristina De Vera Mudry,Heather Hinton,Flavio Crameri,Jose Saro,Stefan Evers,Christian Gerdes,Marina Bacac,Guus A.M.S. van Dongen,Ekkehard Moessner,Pablo Umana +29 more
TL;DR: Preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
Journal ArticleDOI
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.
Christina Claus,Claudia Ferrara,Wei Xu,Johannes Sam,Sabine Lang,Franziska Uhlenbrock,Rosmarie Albrecht,Sylvia Herter,Ramona Schlenker,Tamara Hüsser,Sarah Diggelmann,John Challier,Ekkehard Mössner,Ralf Hosse,Hofer Thomas U,Peter Brünker,Catherine Joseph,Jörg Benz,Philippe Ringler,Henning Stahlberg,Matthias E. Lauer,Mario Perro,Stanford Chen,Christine Küttel,Preethi Latha Bhavani Mohan,Nicolini Valeria G,Martina Carola Birk,Amandine Ongaro,Christophe Prince,Reto Gianotti,Gregory O. Dugan,Christopher T. Whitlow,Kiran Kumar Solingapuram Sai,David L. Caudell,Armando G. Burgos-Rodriguez,J. Mark Cline,Michael Hettich,Maurizio Ceppi,Anna Maria Giusti,Flavio Crameri,Wouter H. P. Driessen,Peter N. Morcos,Anne Freimoser-Grundschober,Victor Levitsky,Maria Amann,Sandra Grau-Richards,Thomas von Hirschheydt,Stella Tournaviti,Michael Molhoj,Tanja Fauti,Viola Heinzelmann-Schwarz,Volker Teichgräber,Sara Colombetti,Marina Bacac,Alfred Zippelius,Christian Klein,Pablo Umana +56 more
TL;DR: FAP– and CD19–4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.
Journal ArticleDOI
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Marina Bacac,Sara Colombetti,Sylvia Herter,Johannes Sam,Mario Perro,Stanford Chen,Roberta Bianchi,Marine Richard,Anne Schoenle,Nicolini Valeria G,Sarah Diggelmann,Florian Limani,Ramona Schlenker,Tamara Hüsser,Wolfgang F. Richter,Katharine Bray-French,Heather Hinton,Anna Maria Giusti,Anne Freimoser-Grundschober,Laurent Lariviere,Christiane Neumann,Christian Klein,Pablo Umana +22 more
TL;DR: CD20-TCB and Gpt represent a potent and safer approach for treatment of lymphoma patients and are currently being evaluated in phase I, multicenter study in patients with relapsed/refractory non-Hodgkin lymphoma.
Journal ArticleDOI
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Laurence B. Peterson,Charles J.M. Bell,Sarah Howlett,Marcin L. Pekalski,Kevin Brady,Heather Hinton,Denise Sauter,John A. Todd,Pablo Umana,Oliver Ast,Inja Waldhauer,Anne Freimoser-Grundschober,Ekkehard Moessner,Christian Klein,Ralf Hosse,Linda S. Wicker,Linda S. Wicker +16 more
TL;DR: A next-generation immunotherapy using a long-lived and Treg-selective IL-2 that activates and expands functional Tregsin vivo is described to the extent that their autoimmune disease condition dictates opening up the possibility for remissions and cures.